What is the Gland Pharma PE ratio today?
Gland Pharma's PE ratio is 44.9 at the 29 October 2026 close (₹3,074.50 a share): a market capitalisation of ₹50,717 crore divided by consolidated net profit of ₹1,129 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1,027 crore) it is 49.4.
What is the Gland Pharma net worth?
Gland Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹10,358 crore on 31 March 2026, up 13.2% from ₹9,151 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹50,717 crore at the 29 October 2026 close.
What is the Gland Pharma book value per share?
Gland Pharma's book value per share was ₹627.91 on 31 March 2026: shareholders' equity of ₹10,358 crore divided by the 16.5 crore shares in issue, up 13.1% from ₹555.40 a year earlier. The share price at the 29 October 2026 close was ₹3,074.50.
What is the Gland Pharma PB ratio (price to book value)?
Gland Pharma's price-to-book (PB) ratio is 4.90 at the 29 October 2026 close: a market capitalisation of ₹50,717 crore divided by shareholders' equity (book value) of ₹10,358 crore on 31 March 2026. That is a book value of ₹627.91 per share against a share price of ₹3,074.50.
What is the Gland Pharma ROE and ROCE?
In FY26, Gland Pharma's return on equity (ROE) was 10.5% and its return on capital employed (ROCE) was 11.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 7.8% and ROCE 9.4%.
What is the Gland Pharma dividend yield?
Gland Pharma's dividend yield is 0.65% at the 29 October 2026 close: dividends of ₹20 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹3,074.50. They were ₹20 on 11 August 2026.
What is the Gland Pharma market cap?
Gland Pharma's market capitalisation was ₹50,717 crore at the 29 October 2026 close: 16.5 crore shares at ₹3,074.50 each.
What is the Gland Pharma EPS?
Gland Pharma's basic earnings per share (EPS) were ₹62.35 in FY26, against ₹42.40 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹68.51.
What is the Gland Pharma dividend in 2026 and its record date?
In 2026, Gland Pharma has declared one dividend: ₹20 with record date 11 August 2026.
Is Gland Pharma debt free?
No. Gland Pharma had borrowings of ₹243 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.02. Its cash and current investments were ₹3,359 crore, so it held net cash of ₹3,116 crore.
What is the Gland Pharma debt to equity ratio?
Gland Pharma's debt-to-equity ratio was 0.02 on 31 March 2026: borrowings of ₹243 crore against total equity of ₹10,358 crore. A year earlier, on 31 March 2025, it was 0.03.
What is the Gland Pharma promoter holding?
Promoters held 45.75% of Gland Pharma on 30 September 2026, down 6.02 percentage points from 51.77% the previous quarter and down 6.08 percentage points from 51.83% a year earlier, according to the shareholding pattern filed with NSE.
What is the Gland Pharma shareholding pattern?
On 30 September 2026, Gland Pharma's shares were held by promoters 45.75%, foreign portfolio investors (FII/FPI) 10.36%, domestic institutions (DII) 33.21% (including mutual funds at 29.52%) and retail and other non-institutional investors 10.66%. Over the year, FII holding was up 2.45 percentage points from 7.91% and DII holding was up 0.57 percentage points from 32.64%.
What are the Gland Pharma latest quarterly results?
Gland Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 10 August 2026: consolidated net profit ₹317 crore, up 47.1% from ₹215 crore in Q1 FY26; revenue from operations ₹1,800 crore, up 19.6% year on year.
What is the Gland Pharma revenue and profit in FY26?
In FY26 (April 2025–March 2026), Gland Pharma's consolidated net profit was ₹1,027 crore, up 47.1% from ₹699 crore in FY25, on revenue from operations of ₹6,431 crore (up 14.5%). Over three years, from FY23, net profit was up 31.5%.
What is the Gland Pharma free cash flow?
In FY26, Gland Pharma generated ₹1,031 crore of cash from operations and spent ₹494 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹537 crore. In FY25 it was ₹521 crore.
When are the Gland Pharma next results?
Gland Pharma will announce its Q2 FY27 results (July–September 2026) on Friday, 6 November 2026, the date of the board meeting it has notified to the exchanges.
Gland Pharma vs Divi's Labs: how do they compare?
In FY26, Gland Pharma earned net profit of ₹1,027 crore on revenue of ₹6,431 crore, against ₹2,568 crore on ₹10,560 crore for Divi's Labs. Gland Pharma's operating margin was 18.8% (Divi's Labs 28.2%) and its return on equity 10.5% (Divi's Labs 16.2%). At the 29 October 2026 close, Gland Pharma's market capitalisation was ₹50,717 crore against ₹2,56,096 crore for Divi's Labs, and its PE ratio on FY26 profit 49.4 against 99.7.
How does Gland Pharma compare with its peers?
On FY26 consolidated figures, against Divi's Labs, Aurobindo Pharma and Piramal Pharma: Gland Pharma's operating margin of 18.8% is the second highest of the four (Divi's Labs 28.2%, Aurobindo Pharma 15.1%, Piramal Pharma 1.0%; peer average 14.8%); its return on equity of 10.5% is the second highest of the four (Divi's Labs 16.2%, Aurobindo Pharma 9.9%, Piramal Pharma −4.0%; peer average 7.4%); its revenue growth over three years of 21.1% a year is the highest of the four (Divi's Labs 10.8% a year, Aurobindo Pharma 10.6% a year, Piramal Pharma 7.8% a year; peer average 9.7% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
